Self-assembling nanoparticle drug delivery system
A self-assembling nanoparticle drug delivery system for the delivery of drugs including peptides, proteins, nucleic acids or synthetic chemical drugs is provided. The self-assembling nanoparticle drug delivery system described herein includes viral capsid proteins, such as Hepatitis B Virus core protein, encapsulating the drug, a lipid bi-layer envelope and targeting or facilitating molecules anchored in the lipid bilayer. A method for construction of the self-assembling nanocparticle drug delivery system is also provided.
1. A self-assembling nanoparticle drug delivery system comprising:
a capsid comprised of non-replicating viral capsid protein, wherein said viral capsid protein is a modified Hepatitis B Virus (HBV) core protein;
a drug captured in said capsid; and
a lipid envelope covalently attached to said capsid, thereby enveloping said capsid.
2. The self-assembling nanoparticle drug delivery system of claim 1 wherein said HBV core protein is mutated such that at least one amino acid of SEQ ID NO. 1 or SEQ ID NO. 2 selected from the group consisting of phenylalanine 23, aspartic acid 29, threonine 33, leucine 37, valine 120, valine 124, arginine 127, tyrosine 132, glutamic acid 77, aspartic acid 78 and alanine 80 is changed to a cysteine.
3. The self-assembling nanoparticle drug delivery system of claim 1 wherein said lipid envelope comprises phospholipids.
4. The self-assembling nanoparticle drug delivery system of claim 3 wherein said phospholipids are selected from the group consisting of phosphotidyl ethanolamine, phosphatidyl glycerol and hydrogenated soy phosphatidylcholine.
5. The self-assembling nanoparticle drug delivery system of claim 1 , wherein said HBV core protein has the amino acid sequence of SEQ ID NO. 1 or SEQ ID NO. 2.
6. The self-assembling nanoparticle drug delivery system of claim 1 , wherein said drug is selected from the group consisting of peptides, proteins, nucleic acids and small molecule synthetic chemical drugs.
7. The self-assembling nanoparticle drug delivery system of claim 1 further comprising at least one of a cholesterol-tagged polyethylene glycol, and a polyethylene glycol-phospholipid.
8. The method of claim 1 wherein said lipid envelope is covalently attached to said capsid though a maleimide intermediate.
9. A self-assembling nanoparticle drug delivery system comprising:
a capsid comprised of non-replicating viral capsid protein, wherein said viral capsid protein comprises a modified Hepatitis B Virus (HBV) core protein;
a drug captured in said capsid; and
a lipid envelope covalently attached to said capsid through a maleimide intermediate, thereby enveloping said capsid.
10. The self-assembling nanoparticle drug delivery system of claim 1 wherein said lipid envelope comprises phosphatidyl glycerol, hydrogenated soy phosphatidylcholine, and cholesterol.
11. The self-assembling nanoparticle drug delivery system of claim 2 , wherein the glutamic acid at amino acid 77 of SEQ ID NO. 1 or SEQ ID NO. 2 is changed to a cysteine.
12. The self-assembling nanoparticle drug delivery system of claim 11 wherein phosphatidyl-ethanolamine maleimide is attached to the cysteine at amino acid 77 of SEQ ID NO. 1 or SEQ ID NO. 2.
13. The self-assembling nanoparticle drug delivery system of claim 9 , wherein the HBV core protein is selected from the group consisting of SEQ ID NO: 1 and SEQ ID NO: 2, wherein the glutamic acid at amino acid 77 is changed to a cysteine in said SEQ ID NO: 1 or SEQ ID NO: 2.
14. The self-assembling nanoparticle drug delivery system of claim 9 , wherein the HBV core protein is mutated such that at least one amino acid of SEQ ID NO: 1 or SEQ ID NO 2 selected from the group consisting of phenylalanine 23, aspartic acid 29, threonine 33, leucine 37, valine 120, valine 124, arginine 127, tyrosine 132, glutamic acid 77, aspartic acid 78 and alanine 80 is changed to a cysteine.
15. A self-assembling nanoparticle drug delivery system comprising:
a capsid comprised of non-replicating viral capsid protein, wherein said viral capsid protein is a modified Hepatitis B Virus (HBV) core protein comprising the amino acid sequence of SEQ ID NO: 2, wherein the glutamic acid at amino acid 77 is changed to a cysteine;
a drug captured in said capsid; and
a lipid envelope covalently attached to said capsid by a phosphatidyl-ethanolamine maleimide to the cysteine at amino acid 77 of SEQ ID NO: 2, thereby enveloping said capsid.